

CDT SUBJECT INDEX TO VOLUME 7

- ABC efflux pumps 894
 mechanism of action of 894
 structure of 894
- ABC transporters 893
 functions of 893
 physiological role of 898
 structure of 893
- ABCB1 1643
- Acute *Candida albicans* infections 483
 host-pathogen interactions of 483
 in mice 483
 pathological consequences of 483,489
- Adenosine biological function of 699
 biological function of 699
- Adenosine receptors 699
 as therapeutic targets for drug development 699
 in chronic airway inflammation 699
- Adipokines 767
- Ageing 1531,1539,1553
 drug development for 1539
 effect of small molecule inhibitors of SIR2/
 related enzymes 1557
 endocannabinoid system in 1539
 genetics of 1531
 molecular mechanisms of 1531
 role of NAD⁺ dependent histone
 deacetylases (sirtuins) in 1553
- Age-related extracellular damage 1469
 pharmaceutical repair of 1469
- Airway diseases 683
 anti-inflammatory therapy of 683
- Airway epithelial cells (AEC) 541
 implications for regulation of airway
 inflammation 541
- Airway inflammation 542
 pathogenesis of 542
- Airway remodeling 584
 in angiogenesis 585
 in mucus gland hypertrophy 585
 in smooth muscle hypertrophy 585
- Airway smooth muscle 525
 contraction of 528
 effect of anti-cholinergics 535
 effect of combination therapy 534
 effect of glucocorticoids 531
 effect of leukotriene receptor antagonists 534
 effect of β_2 -agonists 532
 effects of airway inflammation on 529
 effects of anti-asthma medications on 529
 function of 525
 hyperresponsiveness of 528
 in airway remodeling 528
 interactions with asthma therapies 525
 phenotype of 525
 phenotype plasticity of 525,528
 phenotype switching of 527
- regulation of contraction of 528
 regulation of gene transcription of 527
- Allergic disease 3
 CC chemokines in 3
 CXC chemokines in 6
 receptors implicated in 3
- Allergy 3
- Alzheimer's disease (AD) 1389
 effects of GSK-3 on 1393
 pathology/pathogenesis of 1389
- Anaphylactic shock 1199
 MB in 1199
- Angiogenesis 371,397
 curcumin inhibits aminopeptidase N
 (APN) for 399
 inhibition of 371
 natural anti-angiogenic drugs for 372
 pathophysiology of 371
 role of forward chemical genomics 397
 role of reverse chemical genomics 397
- Annexins 602
- Anti-ageing agents 1532
 small-molecular based 1532
- Antiageing therapy 1505
 low molecular weight thiols as target for 1505
- Anti-asthma medications 573
- Antibiotics 232,795
- Anti-cancer drugs 267,873,1067
 analytical/bioanalytical applications of 1074
 analytical/biomedical applications of 1067
 and drug transporters 873
 biomedical/clinical applications of 1075
 fluorescence methodologies for 1073
 fluorescence spectral properties of 1068
 fluorescence studies of 1067
 protection of hematopoietic cells from
 chemotherapy with 873
 search for 267
- Antidepressant drugs 187
- Anti-drugs 1607
 RNA as target for 1607
- Antifungal drugs 465
 reduced sensitivity to array of 465
- Anti-inflammatory therapy 657
 approaches to 657
- Antimalarial drugs 935
 chloroquine resistance reversal agents as 935
 genes involving in resistance of 936
- Antimicrobial peptide 743
 antimicrobial function of 745
 applications of 743
 as novel therapeutics 747
 biology of 743
 non-antimicrobial functions of 746
 therapeutics of 743

- Antimitotic agents 305
 actin binding drugs as 318
 classification of 305
 drugs binding to sulfhydryl groups as 310
 HDAC inhibitors as 320
 microtubule stabilizing drugs as 306
 of natural origin 305
 proteasome inhibitors as 316
 role of colchicine binding site 307
 role of DNA topoisomerase 317
 role of histone deacetylase (HDAC) 319
 role of kinesin 321
 role of microtubule associated proteins 322
 role of phosphatases 315
 role of vinca binding domain 309
 tubulin destabilizing agents as 307
- Antipsychotics 1206, 1217, 1681
 body weight by 1681
 extrapyramidal symptoms by 1206
 mechanisms of action of 1212, 1682
 obesity by 1681
 pharmacogenetics of 1682
 pharmacogenomic of 1688
 side effects of 1208, 1681
 susceptibility genes for 1681
 tardive dyskinesia by 1207
- Antiretroviral drug 1595
 and tat interactions 1595
 targets for 1595
- Antirheumatic therapy 98
 anti-chemokine targeting in 98
- Anxiety 1660
- Anxious personality traits 1660
- AP12-malt1 1335
 in NF- κ B activation 1336
 structural organizations of 1335
- APOBEC3G 1583
 increasing cellular/virion associated 1586
- Apoptosis 1361
 gene transfer approaches to 1362
 in cancer 1361
- Artemisinin 407
 derivatives of 407
 in angiogenesis 418
 in apoptosis 416
 in cancer cells 407
 in oxidative stress 414
 in proliferation 408
 molecular pharmacology of 407
 pharmacogenomics of 407
 specific target proteins of 418
- Artemisinin derivatives 407
 cytotoxic activity of 407
 in angiogenesis 418
 in apoptosis 416
 in oxidative stress 414
 in proliferation 408
- Arterial occlusion 1285
 anti-factor Xa agents for 1285
 bivalent direct thrombin inhibitors for 1286
- bivalent vs. univalent direct thrombin
 inhibitors for 1288
 direct thrombin inhibitors for 1285
 direct Xa inhibitors for 1289
 indirect Xa inhibitors for 1289
 thrombin inhibitors for 1285
 univalent direct thrombin inhibitors 1288
- Asthma 3,541,547,589,618,691,700,721,1697
 A₁ adenosine receptor in 701
 A_{2A} adenosine receptor in 702
 A_{2B} adenosine receptor in 703
 A₃ adenosine receptor in 704
 activator protein-1 (AP-1) for 590
 β 2-adrenergic receptor pathway in 1700
 airway hyperresponsiveness in 553,730
 airway resident cells in 695
 airway smooth muscle in 556
 B lymphocytes in 693
 CCAAT/enhancer binding proteins
 (C/EBP) for 591
 corticosteroid pathway in 1704
 eosinophils in 694
 epithelial cells in 695
 epithelium in 541
 epithelium in 554
 exhaled no in 726
 fibroblast/subepithelial fibrosis in 555
 GATA-3 for 591
 immune cells in 692
 importance of adenosine in 700
 inflammatory cells in 553
 inhibition of MAPK cascades in animal
 models of 696
 leukotriene antagonist pathway in 1702
 mast cells in 694
 Nrf2/ARE for 592
 nuclear factor kappaB (NF κ B) for 591
 peroxisome proliferator-activated receptor
 (PPAR) 592
 pharmacogenetic phenotypes of 1698
 pharmacogenetics of 1705
 signal transducer/activator of transcription
 6 (STAT6) for 592
 structural remodeling in 554
 T lymphocytes in 692
 targeting mitogen-activated protein
 kinases for 691
 targeting zinc metabolism in 621
 therapeutic approaches to 556
 transcription factors in 589
 Zn deficiency in 618
- Atherosclerosis 13
 CCL2 (MCP-1) in 15
 CCL5/RANTES in 18
 cell migration in 14
 chemokine inhibition in 21
 chemokines in 13
 chemotactic function in 20
 CX3CL1/fractalkine in 19
 CXCL8/IL-8 in 18
 CXCR3 in 19
 receptor CCR2 in 15
 receptor CX3CR1 in 19
 therapeutic targets in 13

- Atherothrombosis 1275
 effect of cyclooxygenase inhibition 1275
 low-dose aspirin 1276
 non-selective cyclooxygenase inhibition in ... 1277
 selective COX-2 inhibitors in 1279
- B cell malignancies 1371
 adoptive T cell therapy for 1373
 DC-based immunotherapy for 1371
 gene therapy for 1372
 idiotype vaccines against 1371
 immunotherapy in 1371
 role of tumor associated antigens (TAA) 1371
- Bacteria 823
 mechanism of plasmid curing in 823
- Bacterial sepsis 119
 chemokines in 119
- BC110/MALT1 signaling pathway 1335
 as drug target in lymphoma 1335
- BCL10 proteins 1335
 in malignancy 1338
 structural organizations of 1335
- Benzo[a]phenothiazines 1083
 dipole moments of 1086
 inclusion complexes with cyclodextrins 1088
 luminescence of 1083
 photophysical properties of 1083
 spectroscopic/photophysical studies of 1083
 therapeutic/analytical applications of 1083,1090
- Benzo[a]phenoxazines 1056
 antimutagenic activity of 1057
 antiproliferative activity of 1057
 antitumor activity of 1056
 radical scavenging activity of 1057
 tumor necrosis factor (TNF)-inducing
 activity of 1057
- Biodiversity 265
 as resource for drug development 265
 as source of anticancer drugs 265
 based therapeutic strategies of future 271
 intellectual property issues in 269
 search for predictive based 269
- Bioengineering 408
 role for synthetic drugs 408
- Biofilms 465
 role in resistance of pathogenic *Candida* to
 antifungal agents 465
- Bipolar disorder 1217
 antipsychotic medications in 1217
 aripiprazole for 1222
 clozapine for 1222
 first generation antipsychotics for 1217
 olanzapine for 1218
 quetiapine for 1221
 risperidone for 1219
 second generation antipsychotics for 1218
 ziprasidone for 1220
- Blood lymphocytes 37
 in EAE 37
 in MS 37
- Body weight gain 1681
- Bortezomib 1344
 in combination with agents in myeloma 1344
 in non-Hodgkin's lymphoma 1345
 phase III trial of 1344
- Brain 39,1515
 chemokines in ischemia to 39
 localization of monoamine oxidase A/B in 1515
- Bruton's tyrosine kinase (BTK) 327
 in autoimmune disease 333
 in transplantation 333
 in treatment of cancer 336
 in type 1 diabetes 334
 inhibitors of 337
 rationally-designed inhibitors of 330
 with rationally-designed inhibitors 327
- Cancer 57,443,1361
 butyrate in 443
 chemokines in 57
 diallyl disulfide in 443
 histone acetylation in 444
 modulation of Bcl-2 family members for 1365
 modulation of death receptor pathways for 1363
 pharmacological modulators of apoptosome-
 dependent caspase activation in 1366
 pharmacological restoration of P53 function
 for 1365
 sulforaphane in 443
 therapeutic targeting of apoptotic
 pathways in 1361
- Candida* 465
 mechanisms of antifungal resistance in 467
- Candida albicans* 483,505
 colonization of 484
 host recognition of 484
 invasion of 485
 methods to study cell wall dynamics in 506
 proteomic approaches to study cell wall
 dynamics in 508
 transcriptional approaches to study cell
 wall dynamics in 508
 virulence traits of 484
- Candida albicans* infections 495
 drug resistance to 501
 epidemiology of 495
 incidence of 497
 risk factors/prognosis of 497
 role of non-*Candida albicans* yeasts in 495
- Carbohydrates 597
 in health/disease 597
 mediated cell-cell interaction/migration 603
- Cardiocirculatory shock 1195
 endothelial dysfunction in 1195
 nitric oxide in 1195

- Catecholaminergic agents 155
 as augmentation strategies in treatment-resistant depression 155
- CCR1 5
 ligand of 5
- CCR4 5
 ligand of 5
- CCR8 6
 ligand of 6
- Cell cycle 1349
 abnormalities in human B-cell lymphomas ... 1350
 control in intact cells 1349
- Cell functions 13
 chemokines/chemokine receptors in 13
- Cell junctions 773
- Cell surface glycans 598
 in development 598
 in malignant transformation/metastasis 598
 to mediate host-microbe interactions 598
- Cell suspension cultures 454
 for paclitaxel/related taxane production 454
- Cell wall 505
 general architecture of 505
 of fungal pathogen 505
- Central nervous system (CNS).....29,1542
 age-related changes of endocannabinoid system in 1542
 CCL2-CCR2 in disease of 38
 CCL3/CCR1/CCR5 in disease of 39
 chemokines in disease of 29
 CXCL10-CXCR3 in disease of 38
- Chemical genetics/genomics 397
 discovery of new small molecules by 397
 to targets angiogenesis *via* 397
- Chemokine receptors66,81,669
 as therapeutic targets in lymphoproliferative disorders 87
 expression in lymphoproliferative disorders 87
 in B cell lymphoproliferative disorders (B-LPD) 82
 in experimental models of glomerulonephritis/organ transplantation 70
 in human inflammatory renal disease 75
 in lymphoproliferative disorders 82
 in renal inflammatory disease 76
 in T cell lymphoproliferative disorders (T-LPD) 85
 leukocyte trafficking in 669
- Chemokinergic system 35
 in EAE 35
 in MS 35
- Chemokines 3,29,47,65,81,91,103,119,579
 expression in ischemic brain tissue 39
 expression in lymphoproliferative disorders 87
 functional groups of 68
 in angiogenesis 58
 in B cell lymphoproliferative disorders (B-LPD) 82
 in bacterial sepsis 119
 in blood-brain barrier disruption associated with neurodegenerative disease 32
 in burn-associated bacterial sepsis 122
 in burn-associated impairment of host anti-bacterial resistance 120
 in cancer 82
 in experimental models of glomerulonephritis/organ transplantation 70
 in gastrointestinal disorders 51
 in HIV-associated dementia 40
 in Hodgkin's disease (HD) 87
 in human inflammatory renal disease 75
 in IBD 52
 in inflammation 581
 in intestinal homeostasis 50
 in intestine 48
 in lymphoproliferative disorders 82
 in neurodegenerative disease 29
 in renal inflammatory disease 76
 in rheumatoid arthritis 91
 in severe asthma 579
 in systemic lupus erythematosus (SLE) 95
 in T cell lymphoproliferative disorders (T-LPD) 85
 molecule family of 66
 receptors expression of 29
 role in kidney 69
 role on basophils 582
 role on cells 582
 role on eosinophils 581
 role on neutrophils 582
 role on T cells 582
 targeting herpesvirus reliance of 103
 targeting of 7
- Chemoprevention244
- Chloroquine935
 antimalarial mode of action of935
 models of resistance of936
 resistance of936
- Cholesterol 1616
- Chronic inflammatory lung diseases751
 aspartic proteases in752
 cysteine proteases in752
 matrix metalloproteases in751
 role of proteases751
 serine proteases in751
- Chronic lymphocytic leukemia (CLL)1313
 gene expression in 1313,1318
 gene products as prognostic parameters for ...1321
 genetics of1313
 genomic aberrations in1313
 protein expression in1320
 rearrangement/mutation status of VH genes in1313
 targeted therapies in clinical trials for .. 1313,1322
 therapeutic targets for 1318,1320
- Chronic obstructive pulmonary disease (COPD)..... 649,669,675,699,707,743
 antimicrobial peptide in743
 antioxidant enzyme mimetics in713
 antioxidant therapeutic interventions in707,710
 as chronic inflammatory disease649
 cathelicidins in745

- cell-derived ROS in 708
 chemokines in 679
 chemokine receptors in 669
 chemokine receptors on lung resident cells in 671
 corticosteroid responsiveness in 656
 corticosteroids in 650,680
 cytokine profile in 676
 cytokines as targets in 675,679
 defensins in 745
 differential expression of homing receptors
 on TH1/Th2 cells in 670
 effect of cigarette smoke 707
 epithelial expression of cytokines in 676
 erdosteine in 713
 exacerbations of 677
 growth factors in 678
 IL-1 β in 678
 IL-8 in 678
 inflammation in 675
 inhaled oxidants in 707
 leukocyte recruitment in 671
 macrophage release of cytokines in 677
 N-acetylcysteine (NAL) in 713
 N-isobutylcysteine (NIC) in 713
 oxidative stress in 715
 oxidative stress in lung tissue in 709
 oxidative stress measurement in 710
 PDE inhibitors in 680
 phosphodiesterase 4 inhibitor in 714
 polyphenols in 717
 potential roles of AMPs in 746
 redox sensor molecules in 714
 role of infection/innate immunity in 743
 role of neutrophils in 670
 role of T cells in 671
 signal transduction in 715
 steroid efficacy in 715
 T-cell-derived cytokines in 678
 therapies for 672
 TNF α in 677,679
 VEGF in 679
 Circulatory shock vasoplegia 1197
 MB guanylyl cyclase inhibition as
 therapeutics for 1197
 CMV encoded chemokines 106
 receptors for 106
 Corticosteroids 649
 molecular mechanisms of 649
 oxidants in 650
 Cryptococcosis 516
 Cyclooxygenase 1275
 isoforms/products of 1275
 CYP2D6 1671
 in psychological functioning 1673
 pheno/genotyping 1671
 CYP2D6 genetic polymorphism 1671
 and antipsychotic drugs 1677
 clinical implications of 1671
 during treatment with antipsychotic drugs 1671
 in patients treated with antipsychotic drugs ... 1674
 relevance for drug plasma concentration
 in patients 1676
 Cysteine proteases 753
 antigen presentation of 754
 in allergic diseases 754
 in fibrosis 755
 in infectious diseases 755
 in pneumonia 755
 in proteolytic networks 753
 in tumors 756
 Cysteine supplementation 1509
 effect of 1509
 Cytochrome P₄₅₀ 1709
 Cytokines 675
 chemokines as 676
 classification of 675
 lymphokines as 675
 Dendritic cells (DC) 541,1563
 epithelial cell regulation of 543
 implications for regulation of airway
 inflammation 541
 in asthma 543
 in atopy 543
 interactions with airway epithelial cells 541
 models for 1566
 receptors on 1565
 targeting CLRs on 1568
 transmission of HIV by 1566
 Dengue fever 1632
 Dengue virus 1623
 as therapeutic target 1623
 molecular biology of 1624
 non-structural protein 5 (NS5) 1626
 RNA polymerase NS5 of 1623
 Depression 165,203
 clinical effects of T3 in 203
 effect of repeated antidepressant
 administration on 165
 mechanism of action of T3 in 203
 Dopamine 180
 and antidepressant drugs 180
 in depression 180
Drosophila melanogaster 1479
 as model system 1479
 pharmaceutical trials to aging of 1481
 pharmacology of ageing in 1479
 Drug discovery 256
 biodiversity-based 256
 botanical medicine in 260
 ethnopharmacology in 259
 from natural sources 257
 Drug efficacy 388
 chemical proteomics approaches to 390
 effect of aberrant gene expression 388
 effect of sporadic mutations 388
 genome-wide transcriptional profiling of 389
 Drug resistance 389
 adaptive responses in 389
 small molecule/target validation studies in 392
 Dual NK-1/NK-2 antagonists 986

- Endocannabinoid system 1539
immunomodulatory effects of 1542
neuromodulatory effects of 1542
- Epithelial cell 543
methods to study 543
- Epithelial injury 598
- Epithelial repair 597
post-translational modification in 597
role of cell surface glycoconjugates in 600
- Epstein-Barr virus (EBV) associated diseases 109
role of host chemokine system in 110
- Ethnobiology 241
role in anti-cancer targets 241
- Ethnobotany 239
in convention of biological diversity 241
role for anti-cancer drug development 239
- Ethnopharmacy 239
role for anti-cancer drug development 239
- Extracellular matrix 567
collagen in 568
effect of anti-asthma medications 573
fibronectin in 568
function in airways 567
glycoprotein in 568
in airway disease 568
in normal airways 568
laminin in 568
proteoglycans in 568
- Folate receptor 230
- Folic acid 230
- Forward chemical genomics 401
curcumin analogue by 401
- Fruit flies 1480
candidate drugs in 1480
drug testing 1480
- Fungal ATP-binding cassette (ABC) transporters 471
clinical relevance of 475
in drug resistance/detoxification 471
mechanisms of drug recognition by 473
physiological functions of 477
substrate specificity of 473
- Fungi 471
ABC transporters in 471
- Galectins 602
- Gastrointestinal disorders 47
chemokines in 47
- Gastrointestinal tumors 58
chemokines in 58
- Genetic variation 1650
in Brazilians 1650
in North Americans 1653
- Genomics 387
applications in HIT/lead identification 393
based approaches 389
role in molecular basis of drug action/
response 387
to study genetic determinants of drug
response 387
- Glucocorticoids 654
effects of oxidative stress on 655
non-genomic actions of 654
- Glucocorticoid receptor 651
effects of long acting β -agonists on 657
functions of 651
gene induction by 652
gene repression by 652
LBD crystal structure of 654
mechanisms of 651
nuclear localization of 651
phosphorylation of 654
- Glucose dysregulation 1438
GSK-3 inhibitors for 1438
- Glucose homeostasis 1435
disruption of 1436
regulation of 1435
- Glutathione 712
biosynthesis of 712
- Glycocojugates 598
in inflammation 598
- Glycogen synthase kinase-3 (GSK-3) 1377,1389,1399,
1411,1421,1435
as drug target in Alzheimer's disease 1389
as protein kinase 1377
as therapeutic target 1385
cell cycle progression in 1384
cloning of 1377
effects of thymoleptic medications on
mediated signaling by 1404
function of 1379
in glucose dysregulation 1437
in glucose metabolism 1383
in Hedgehog signaling 1382
in insulin resistance 1435
in mood disorders 1425
in NF- κ B signaling 1382
in psychiatric diseases 1421
in regulation of developmental specification/
cell polarization 1411
in schizophrenia 1426
in WNT pathway 1380
indirect inhibitor of 1403
intracellular vesicular transport of 1383
linked pathways 1411
modes of regulation of 1377
modulation of apoptosis/cell survival by 1384
modulation of microtubule growth by 1383
neuronal functions regulated by 1429
regulation of 1421
regulation of transcription factors by 1382
structure of 1379
studies of human genetics/rodent behavior 1405
targeting in CNS 1399
therapeutic interventions by 1421

- G-protein 1253
 dependent platelet signaling 1253
 in platelet activation 1254,1256
- GSK inhibitors 1390
- GSK-3 β 1455
 homologs of 1455
- Guanylyl cyclase 1195
 as vasoplegic circulatory shock
 therapeutic target 1195
 inhibition by MB 1195
- Hematologic malignancies 1301,1341
 bortezomib for 1342
 immunotoxins for 1301
 proteasome inhibitors for 1342
 role of proteasome inhibition 1341
 surface targeted therapies for 1301
 therapeutic principle in 1341
 ubiquitin-proteasome pathway in 1341
- Herpesvirus 103
 role of chemokine system 103
- α -Herpesviruses 103
- β -Herpesviruses 103
- γ -Herpesviruses 109
- HIF-1 α protein synthesis 356
 inhibitors of 356
- Histone deacetylases 443
 as targets for dietary cancer preventive agents 443
- Histone deacetylases class I/II 1553
- Histone deacetylase inhibitors 445,773
 as modulators of cellular contacts 773
 butyrate in 447
 diallyl disulfide in 448
 for cancer prevention 445
 sulforaphane in 449
- HIV 1599,1607
 gene expression of 1599
 lifecycle RNA intermediates of 1607
 RNA splicing/translation of 1608
 role of histone deacetylase/acetyl-
 transferase activity 1599
 targeting RNA in treatment of 1610
 transcription of 1607
- HIV infection 881,1575
 down-regulated IL-7 α expression on
 T-cells in 1575
 novel strategies for 881
 reversal of HIV drug resistance in 881
 role of viral infectivity factor Vif 881
 tool of therapy for 881
- HIV-1 1563
 approaches to microbicide development
 based on CLR biology of 1567
 effect of female genital tract 1564
 microbicides in 1563
 mucosal transmission of 1563
 nonoxynol-9 (N-9) in 1563
 role of dendritic cells 1563
 targeting with soluble CLRs 1567
- HIV-1 genome 882
 mutation spectrum of 882
- HIV-1 long terminal repeat (LTR) 1596
- HIV-1 multidrug resistance 882
 reversal of 882
 role of cellular apobec3G cytidine
 deaminase in 882
- Homeostasis 773
 gatekeepers of 773
 histone deacetylase inhibitors as
 modulators of 776
- Host chemokine system 108
 CMV regulation of 108
- Host defense 1607
 RNA as target for 1607
- 5-HT system 140,153
 effects of catecholaminergic drugs on 153
- 5-HT_{1A} autoreceptors 140
 antidepressant effect of 140
 blockade to improve antidepressant drug
 action 141
- 5-HT₂ receptors 179
 central dopaminergic function of 179
- 5-HT_{2C} 165
 in depression 169
 modulation of dopamine transmission by 165
 role in antidepressant response 165,169
- 5-HT₃ receptors 165
 in depression 172
 modulation of dopamine transmission by 165
 role in antidepressant response 165,172
- Human cancers 864
 significance of MDR positivity in 864
- Human cancer cells 816
 delivery of anti-MDR1/P-GP siRNAs/
 shRNAs to 816
- Human immunodeficiency virus (HIV) 1583
 antivirals against 1583
 degradation of 1586
- Human MVP expression 930
 factors regulating 930
- Hypoxia-inducible factor-1 (HIF-1) 355
 inhibitors for 365
 inhibitors of interaction of 364
 natural product-based inhibitors of 355
- Immune response 487
 mammalian host-pathogen recognition 487
- Immunotoxins 1301
 development of 1306
 in treatment of hematologic malignancies 1301
 targeting hematologic tumor antigens 1303

- Individualized medicine 1721
 clinical application of 1721
 ethical/social issues in 1721
- Inflammation 650
 oxidants in 650
- Inflammatory bowel disease (IBD) 51
 CC chemokines in 56
 CXC chemokines in 52
- Inflammatory lung disease 663
 NF- κ B activation pathway in lung epithelial
 cells in generation of 663
- Inflammatory neutrophils 714
 inhibition of superoxide production from 714
- Inhibitory kappa B kinases (IKK) 661
 regulation of 661
- Integrins 567
 as targets for drug therapy 573
 expression in airway epithelium 570
 expression in airway mesenchymal cells 570
 expression in inflammatory cells 571
 expression in smooth muscle progenitor
 stem cells 570
 function in airways 567
- Interleukin-7 (IL-7) 1571
 biology of 1571
 IL-7 in 1575
 in T-cell homeostasis 1574
 role in B/T-cell lymphogenesis 1573
 role in latent viral reservoirs 1578
 therapeutic based 1578
- Interleukin (IL-7/IL-7) receptor 1571
 central role in T-cell homeostasis 1571
 expression of 1572,1577
 in immune reconstitution 1577
 regulation of 1572
 signaling of 1572
- Invasive aspergillosis (IA) 516
- Invasive candidosis 515
- Invasive fungal infections 513
 amphotericin B in 517
 antigen/antibody detection in 515
 azoles in 518
 culturing techniques for 514
 1-3- β -D-glucan as marker for 516
 echinocandins in 519
 fluconazole in 518
 5-fluorocytosine in 518
 itraconazole in 518
 laboratory diagnosis of 513
 microscopy for 513
 therapy for 513,517
 triazoles in 518
- Janus kinase 3 (JAK3) 327
 in autoimmune disease 333
 in transplantation 333
 in treatment of cancer 336
 in type 1 diabetes 334
 rationally-designed inhibitors of 330
- targeting by specific inhibitors to alter T-cell
 responses *in vitro* 333
 with rationally-designed inhibitors 327
- Jasmonate/related compounds 454
 as stimulator for production of active
 ingredients 454
- Juvenile idiopathic arthritis (JIA) 95
- Kaposi's sarcoma associated herpesvirus (KSHV) 111
 role of chemokines/receptors 111
 role of host chemokine system 112
- Kidney disease 65
 chemokines in 65
- Leptin 761
 and drugs 765
 body weight regulation by 761
 effect of cannabinoid-1 receptor antagonists 767
 effect of metformin 765
 effect of nicotinic acid 766
 effect of serotonin re-uptake inhibitors 766
 effect of statins 766
 effect of thiazolidinediones 765
 effect of weight reducing agents 766
 in blood pressure 763
 in cardiac function 764
 in carotid artery disease 764
 in renal function 764
 in sex hormones 765
 in stroke 764
 in thrombosis 762
 in vascular smooth muscle cell hypertrophy 762
 therapeutic target with pleiotropic action 761
 vascular biology of 762
- Leukopenia 1191
 by antidepressant medicines 1192
 by antipsychotic medications 1191
 by mood stabilizers 1192
 intervention for 1193
 pathophysiology of 1193
 psychotropic medications in 1191
- Lipid membrane 1615
 as target for viral/bacterial pathogens 1615
- Lipid peroxidation products 650
 in cell signaling/pro-inflammatory gene
 transcription 650
- Lipid rafts 1615
 functions of 1615
 structures of 1615
- Liposomes 870
 encapsulation of anticancer drugs in 870
- Lithium 159,1403
 effect in forced swimming test 160
 mechanism of 159
 molecular effects of 1403
 neurobiochemical effects of 159
 potentiation of antidepressant-like activity
 with 159

- Liver transplantation 1202
 MB in 122
- Lymphoma 1329,1335
 pathogenesis of 1329
 role of murine models 1329
 targeting oncogenic tyrosine kinase NPM-
 ALK in 1329
 treatment options for 1329
- Lymphomagenesis 1331
 therapy validation in mouse models based on 1333
 transgene mouse models of NPM-ALK
 induced 1331
- Lymphoproliferative disorders 81
 chemokines in 81
- Macromolecular anticancer drug delivery systems 229
 role of hyaluronic acid 233
 site-specific targeting of 229
- Macromolecules 232
 RGD/integrin receptors based 232
- Major depression 149
 α_2 -adrenergic antagonists for 151
 catecholamine releasing agent for
 bupropion for 152
 catecholaminergic strategies for 149
 dopaminergic agonists for 153
 monoamine oxidase inhibitors for 160
 selective noradrenergic reuptake
 inhibitors for 149
 treatment of 149
- Major facilitator superfamily (MES) 795
 amplified expression of 801
 circular dichroism spectroscopy of 809
 determination of 3-dimensional structure of ... 805
 recombinant DNA procedures for 808
- Malignant lymphoma 1349
 cell cycle inhibition in 1349
 cell cycle inhibitors for 1353
 clinical trials of 1355
 role of cellular proliferation machinery 1349
- Malt lymphoma 1335
 chromosomal translocations in 1335
- Malt1 1335
 in malignancy 1338
 in NF- κ B activation 1336
 structural organizations of 1335
- Mck1 1455
 in centromere function 1459
 in meiosis 1458
 in meiosis 1460
 in phosphorylation of UME6 1461
 in regulating PKA function 1455
- MDR reverters 949
 cancer cell permeability-glycoprotein as
 target of 949
 role of dihydropyridine derivatives 949
- MDR1/P-glycoprotein (ABCB1) 813
 as target for DNA interference-mediated
 reversal of multidrug resistance 813
- in RNA interference (RNAi) technology 814
 RNAi-mediated inhibition of 819
- Mesenchymal cell 567
 apoptosis in 572
 cell adhesion/migration in 572
 cytokine release in 572
 function in airways 567
 proliferation in 572
- Methicillin resistant *Staphylococcus aureus* (MRSA) 887
 alternative therapy for 887
 in economically disadvantaged countries 887
 management of 887
 non-antibiotic thioridazine for therapy of 889
 non-antibiotics for 887
- Microbial drug efflux proteins 793
 in membrane transport 793
 of facilitator superfamily 793
- Microdialysis 187
 to study selective serotonin reuptake
 inhibitors 187
 to study serotonin outflow in mice 187
 to study substance P (neurokinin 1) receptor
 antagonist administration 187
- Mood disorders 1399,1660
 lithium salts as mediations in 1400
 treatments for 1399
- Movement disorders 1225
 abbreviated dyskinesia scale for 1226
 abnormal involuntary movement scale for 1226
 clinical dyskinesia rating scale for 1227
 Crane rating scales for 1226
 Degwitz/others rating scale for 1226
 extrapyramidal rating scale for 1226
 HANS rating scale for extrapyramidal
 syndromes in 1228
 in schizophrenia 1225
 Maryland psychiatric research center
 scale for 1227
 Obesco dyskinesia scale for 1227
 rating scales in assessment of 1225
 rush dyskinesia scale for 1227
 Simpson tardive dyskinesia rating scale for ... 1226
 Smith tardive dyskinesia scale for 1226
 St. Paul-Ramsey hospital scale for 1226
 unified parkinson's disease rating scale for ... 1227
- MRK1 1461
 in phosphorylation of UME6 1461
- MRP1 914
 as potential drug targets 917
 characteristics of 914
 distribution/localization in normal tissue/
 tumors 915
 mediated resistance to anti-tumor drugs 917
 physiological functions of 916
 substrates transported by 916
- MRP2 914
 as potential drug targets 917
 characteristics of 914
 distribution/localization in normal tissue/
 tumors 915
 mediated resistance to anti-tumor drugs 917

- physiological functions of 916
 substrates transported by 916
- Muco-cutaneous candidiasis 495
- Multidrug resistance 416,813,861,893
 antisense strategies targeting MDR1 mRNA
 to treat 871
 approaches for 865
 efflux pumps in 894
 implications for design of inhibitors of
 PgP/MRP1 to control 893
 in *Salmonella enterica* 849
 modulators for 814
 P-glycoprotein targeting antibodies against 871
 P-glycoprotein tissue distribution in 862
 pharmacological strategies for 861,899
 phenotype of 861
 relationship between ACRA-B-TOLC efflux
 pump/SGL-1 in DT104 isolates from 856
 role of ABC transporters 863
 role of chemical agents 865
 role of P-glycoprotein substrates 862
 small molecules for control of 899
- Multi-drug resistant *Mycobacterium tuberculosis*
 (MDRTB) 887
 alternative therapy for 887
 in economically disadvantaged countries 887
 management of 887
 non-antibiotics for 887
 thioridazine therapy of 889
- Multidrug transporters 911
 as drug targets 911
- N*-acetyl-*L*-cysteine (NAC) 712
- NAD⁺-dependent histone deacetylases 1553
- Nanoparticle 643
 based diagnosis/therapy 643
 in bronchial asthma 646
 in parainfluenza virus infection 647
 in pulmonary tuberculosis 646
 in respiratory diseases 646
 in respiratory syncytial infection 647
 in vaccination strategies 647
 physical dimensions of 643
 physical-chemical properties of 644
 targeting respiratory system by 645
- Nanospheres 870
 encapsulation of anticancer drugs in 870
- Natural anti-angiogenic drugs 371
 adverse effects of 374
 clinical aspects of 371
 clinical translation of 372
 efficacy of 375
 preclinical studies of 372
- Natural flavonoids 345
 activating ATM/ATR/CHK1/2 pathway 351
 combinatorial cell cycle effect of 352
 effect on cell cycle related biological events 352
 effect on G1/S transition-associated cell
 cycle events in cancer cells 347
 in cancer cells 345
- inhibit mitogenic signaling 347
 targeting CDC25C-CDC2-cyclin B1
 regulation 350
 targeting CDK-cyclin activity 347
 targeting deregulated cell cycle progression 345
 targeting expression of CIP/KIP/INK
 proteins 348
 targeting P53 for cell cycle arrest 350
 targeting retinoblastoma family proteins/
 E2FS 348
 targeting survivin 351
- Natural products 247,279,357
 apidine from 297
 as modulators of antitumor targets 279
 ascididernins from 295
 cell cycle/kinase inhibitors from 292
 diazomamide from 286
 dictyostatin from 285
 DNA interactive agents from 294
 eleutherobin/sarcodictin from 286
 from marine invertebrates 279
 from microbes 279
 HDAC inhibitors (HDACIS) from 291
 histones from 290
 indigo/indirubins from 292
 inhibitors of topoisomerases I/II from 289
 laulimalide from 287
 molecules with taxol-like activity from 284
 molecules with vinca-like activities from 281
 peloruside from 287
 proteasome inhibitors from 289
 related drugs in prescription medicine 247
 spisulosine from 295
 to promote HIF-1 α protein degradation 357
 tubulin interactive agents (TIAS) from 280
 zalypsis from 295
- Nitric oxide 1243
 antithrombotic actions of 1243
 dependent thrombosis 1247
 diseases related to 1243
- Nitric oxide synthase (NOS) 721
 as therapeutic target for asthma 721
 function of 721
 in chronic obstructive pulmonary disease 721
 localization in airways 723
 regulation of 721
 structure of 721
- S*-Nitrosothiols 725
 mediated bioactivities 725
- NK1 receptor 191
 acute pharmacological blockade of 193
 genetic/pharmacological inactivation of 191
 knock-out mice of 192
 sustained pharmacological blockade of 193
- NK1 receptor antagonists 195
 effect of acute administration of 195
- NK-1 receptor selective antagonists 975
- NK-2 receptor selective antagonists 981
- NK-3 receptor selective antagonists 984
- NO-dependent thrombosis 1247
 targets for 1247

- Non-antibiotics phenothiazines 888
- Non-*Candida-albicans* species 498
emergence of 498
- Non-Hodgkin's lymphomas (NHL) 1293
I¹³¹ tositumomab for 1296
radioimmunoconjugates for 1293,1298
selection of target for 1293
- NPM-ALK 1329
retroviral infection/transplantation models of 1329
- Nuclear factor kappa B 661
activation pathway of 661
as therapeutic target in inflammatory lung
disease 661
cellular involvement in lung inflammation
via 663
regulatory mechanisms of 663
role in resident macrophages in generation of . 664
role in recruited neutrophils in generation of .. 664
- Nucleus accumbens ` 166
effect of repeated antidepressant administration
on dopamine release in 166
- Oxidative stress 650
in cell signaling/pro-inflammatory gene
transcription 650
- Paclitaxel 453
plant cell culture technology for 458
production of cultures of taxus species 453
regulation of biosynthesis by jasmonates 456
related taxanes of 454
- Parkinson's disease (PD) 1514
neuropathology of 1514
- Peptide antagonists 982
- Peripheral tissues 1544
age-related changes of endocannabinoid
system in 1544
- Peroxidases 1157
as free radicals generators 1157
Horseradish peroxidase (HRP) as 1157
myeloperoxidase (MPO) as 1158
myoglobin (Mb) as 1159
- P-glycoprotein 911,949
calcium channel antagonists as 952
in drug-drug interactions 911
in toxic drug-drug interactions 913
intentional modulation of 911
mechanisms of inhibition of 951
modulators of 949
structure/function of 949
unintentional modulation of function of 913
- Pharmacogenetically relevant genes 1641
ethnic differences in 1641
- Pharmacogenetics 1671,1697,1709
genotype-phenotype correlations of 1714
of asthma therapy 1697
of cytochromes P₄₅₀ in tropical medicine 1709
- Pharmacogenomics 1649,1671
in Americans 1649
studies in admixed populations 1656
- Pharmacogenetics 1644
role of ethnicity in 1644
- Pharmacognosy 247
contribution to drug discovery 254
contribution to modern medicine 247
in modern medicine 247
in pharmacy 247
- Phenothiazines 824,1095,1123,1137,1155
ABC transporters in 839
activity of 1059,1060
antibacterial effect of 824
antiplasmid effects *in vitro* 824,835
as anti- *Trypanosoma cruzi* LADH agents 1156
as chemosensitizers in drug resistant
as inhibitors of P-glycoprotein 1123
as modulators of cancer multidrug resistance 1123
as phototherapeutics 1150
biological effects of 1182
cellular phototoxicity of 1140
cytotoxic potential of 1055
DNA interactions of 1143
DNA photodamage by 1145
evaluation of plasmid curing by 839
in combination treatment 1175
interaction of 1096
interaction with erythrocyte membrane 1099
interactions with lipid bilayer 1095
microorganisms 1100
modes of interaction of 1184
molecular considerations of 1183
multidrug resistance reversal in cancer
cells by 1100
photochemistry of 1138
photophysical characteristics of 1137
plasmids in 839
proteins/lipids photodamage by 1147
related compound 1055
relationship between chemical structure/
role in multidrug resistance reversal 1095
SAR/QSAR of 1128
structurally related compounds of 1123
structure activity relationships of ... 838,1102,1163
use/applications of 1181
- Phenothiazine derivatives 1107
as analytical reagents in spectrophotometry 1107
as analytical reagents 1115
as reagents in gravimetric analysis 1119
extractive spectrophotometric determination
of metals by 1115
for determination of metals 1107
- Phenothiazine-type MDR modulators 1126
drug-membrane interactions of 1126
- Photosensitization 1135
of biomolecules of by phenothiazine
derivatives 1135
- Pindolol 139
antidepressant response by 139
as 5-HT_{1A} receptor antagonist 144
clinical data of 143

- dosage of 144
 5-HT_{1A} receptor occupancy by 144
- Platelet activation 1258
 role of G α_s 1258
 role of G_{12/13} 1258
 role of GTP binding proteins 1258
- Platelet protein disulfide isomerase 1234
 in function of glycoprotein Ib adhesion
 receptor 1238
 in NO release 1236
 role of sulfhydryls in 1235
- Platelets 1233,1265
 effect of activation on labeling of thiols 1237
 effect of glutathione 1237
 effect of GPVI $\alpha_2\beta_1$ /GPIb-IX-V 1269
 negative regulation of signaling by
 PECAM-1 1271
 phosphotyrosine signaling in 1265
 role for vicinal thiols 1238
 role of extracellular thiols/disulfides in 1233
 role of PDI in 1235
 role of S-nitrosothiols 1236
 signaling mediated by integrin $\alpha_2\beta_1$ 1267
 signaling mediated GPIb IX-V complex 1266
- Pleiotropic drug resistance (PDR) 471
- Polymorphisms 387
 to study intrinsic variability in drug response 387
- Premature ageing 1485
 effect of adaptogens 1494
 effect of antioxidants 1491
 effect of caloric restriction 1485
 effect of dehydroepiandrosterone (DHEA) 1489
 effect of enteroabsorbents 1494
 effect of glucocorticoids 1489
 effect of growth hormone 1488
 effect of immunomodulators 1494
 effect of inhibitors of cross-linking 1493
 effect of melatonin 1489
 effect of neurotropic drugs 1493
 effect of peptides modulating pineal function 1490
 effect of sex hormones/contraceptives 1489
 effect of succinic acid 1492
 effect of thyroid hormones 1488
 limitations/perspective of pharmacological
 interventions of 1485
 prevention of 1485
- Protease-activated receptors (PARs) 629
 agonists of 629
 antagonists of 629
 as anti-inflammatory 629
 as pro-inflammatory 629
 effect of activation on gut motility 632
 effect on airway remodeling 633
 effect on airway smooth muscle tone 632
 effect on blood pressure 630
 effect on cardiac remodeling 631
 effect on platelets/coagulation 630
 effect on vascular 631
 effect on VSM tone 630
 expression of 630
 in airways 632
 in cardiovascular system 630
- in gastrointestinal tract 631
 molecular biology of 630
- Proteasome inhibitors 1344
 clinical development of 1344
- Protein kinase 1443
 chemical genetics of 1450
 chemogenomics of 1450
 computational chemistry of 1446
 inhibition of 1445
 library design of 1448
 proteomics approaches of 1450
 selective inhibitor design for 1443
 structural biology of 1444,1446
 substrate/mechanisms based inhibitors of 1449
- Proteomics 387
 role in molecular basis of drug action/
 response 387
 to study genetic determinants of drug
 response 387
 small molecule target identification by 390
- Psoriatic arthritis (PsA) 94
- Psychiatric diseases 1429
 treatment mechanisms in 1429
- Psychopharmaceuticals 1191
- Psychopharmacogenetics 1724
- Pulmonary emphysema 737
 treatment of 737
 vasculature as target in 737
- Oncogenes 416
- Quinoline 940
 drug resistance to 940
 modulators of 940
 role of transporter inhibitors 940
- Quinoline derivatives 843
 as inhibitors of antibiotic efflux pump 843
 effect on *Enterobacter aerogenes* antibiotic
 susceptibility 844
 effect on intracellular accumulation of
 chloramphenicol in *E. aerogenes* resistant
 isolate 844
 in multidrug resistant *E. aerogenes* isolates 843
- Radioimmunotherapy 1293
 of non-Hodgkin's lymphomas 1293
 selection of radioisotopes for 1293
- Rasagiline 1517
 neuroprotective actions of 1517
- Redox modification 1233
 generation of thiols by 1238
 of platelet glycoproteins 1233
- RelA 662
 regulation by posttranslational modifications ..662
- Resveratrol 423,1556
 as adjuvant for chemosensitization/
 radiosensitization 435
 as chemopreventive agent 423

- bioavailability of 436
 for fighting cancer 423
 in carcinogenesis 424
 in promotion 426
 in tumor initiation 424
 role in chemoprevention by activation of
 kinase cascade 435
 role in chemoprevention by cell cycle arrest ... 427
 role in chemoprevention by induction of
 phase II enzymes 425
 role in chemoprevention by induction of
 cell death 431
 role in chemoprevention by inhibition of
 angiogenesis 434
 role in chemoprevention by inhibition of
 phase I enzymes 424
 role in chemoprevention by inhibition of
 polyamine synthesis 426
 role in chemoprevention by inhibition of
 lipid mediators 427
 role in chemoprevention by inhibition of
 nitric oxide 434
 role in chemoprevention by ROS scavenging . 425
 role in chemoprevention by stimulation
 of DNA repair 426
 role in chemoprevention by inhibition of
 kinase cascade 426
 to activates sirtuins 1556
- Rheumatic diseases 91
 chemokines in 91
- Rheumatoid arthritis 91
 C chemokines in 93
 C-C chemokines in 93
 chemokine receptors in 93
 C-X3-C chemokines in 93
 C-X-C chemokines in 92
- RIM11 1461
 in phosphorylation of UME6 1461
- RNAi 818
 off-target effects of 818
- Saccharomyces cerevisiae* 1455
- Salmonella enterica* 849
 development of chromosomal resistance
 gene clusters in 849
 multiple antibiotic resistance in 850
 role of active efflux in antibiotic resistance in 853
- Schizophrenic psychosis 1205
 antipsychotic intervention in 1205
 aripiprazole for 1212
 clozapine for 1207
 first generation antipsychotic drugs for 1205
 olanzapine for 1209
 quetiapine for 1210
 risperidone for 1208
 second generation antipsychotics for 1207
 treatment for 1206
 ziprasidone for 1211
- Selective serotonin reuptake inhibitors (SSRIs) 187
 antidepressant-like efficacy of 187
 to study interactions between cell bodies/
 terminals serofonergic regions 188
- Selegiline 1513
 antiapoptotic actions in neurons 1523
 as calmodulin antagonist 1518
 as monoamine oxidase-B inhibitor 1514
 clinical features of 1514
 effect on life expectancy in rodents 1521
 effect on striatal superoxide dismutase 1522
 in abnormal gait/posture 1513
 in Gilles de la Tourette syndrome 1526
 in global ischemia 1526
 in hypokinesia 1513
 in narcolepsy 1526
 in neurodegenerative disorders 1513
 in neurological diseases 1513
 in rigidity 1513
 in synthesis of nerve growth factor/protects
 central nervous system neurons 1521
 in treatment of Alzheimer's disease 1525
 in treatment of Parkinson's disease 1513,1524
 induces dopamine release 1519
 neurotrophic actions of 1520
 protects dopaminergic neurons from toxicity 1522
 therapeutic efficacy of 1513
 to protects against peroxynitrite/nitric oxide-
 induced apoptosis 1523
 to protects dopaminergic neurons 1521
 to protects dopaminergic neurons from
 glutamate-mediated neurotoxicity 1522
 trophic like action of 1520
- Septic shock 1202
 MB in 1202
- Serotonin 168,1659
 behavior of 1659
 in Alzheimer/Parkinson diseases 1664
 in attention deficit hyperactivity disorders 1663
 in critical neuroanatomic sites 1659
 in eating disorders 1663
 in schizophrenia 1664
 in substance abuse disorders 1662
 induced dopamine release 168
 variants of 1659
- Serotonin-dopamine interaction 177
 central dopaminergic pathways in 177
 central serotonergic system in 176
 5-HT₂ receptor family in 178
 role for novel antidepressant drugs 177
- Severe asthma 581
 airway remodeling in 583
 inflammation in 581
- shRNAs 816
 delivery of 816
- siRNAs 816
 delivery of 816
- Small molecules 1531
 anti-ageing properties of 1531
- Solid tumors 58
 leukocyte infiltrate in 58
- Spondylarthropathies (SqA) 94

- Subproteomes 390
 analysis of 390
- Subepithelial fibrosis 584
 eosinophils in 584
 fibroblast/myofibroblast in 584
 mast cells in 584
 neutrophils in 584
- Substance P 189
 activation of NK1 receptors by 189
 preclinical arguments of 190
- Sulfhydryls 1238
 role in P2Y12 platelet ADP receptor 138
- Synovitis 97
 regulation of chemokine production in 97
- Systemic autoimmune diseases 95
- Systemic Candidiasis 496
- Tachykinins 963,993,1005,1011,1021,1031,1043
 angiogenic effects of 1035
 antagonists for 1008
 antagonists in gastrointestinal disorders 1026
 biological actions of 970
 cardiac effects of 1038
 control of systemic blood pressure by 1037
 distribution of 993
 effect on pulmonary blood flow 1037
 effect on respiratory tract 1007
 expression in immune cells 1012
 expression of 966,1021
 family of 1011
 from vertebrates/ascidians 963
 function of 963
 in affective disorders 997
 in airway inflammation 1007
 in astrocytoma 1044
 in breast carcinoma 1046
 in cancer 1043
 in cardiovascular system 1031
 in drug abuse 999
 in emesis 998
 in glioma 1044
 in hematopoiesis 1014
 in immune system 1011
 in inflammation 1016
 in leukemia 1047
 in melanoma 1047
 in midgut carcinoma 1048
 in nerves/angiogenesis 1034
 in neuroblastoma 1046
 in neuropsychiatric disorders 993
 in pain 995
 in pancreatic cancer 1048
 in Parkinson's disease 999
 in pulmonary hypertension 1037
 in respiratory tract 1005
 in schizophrenia 999
 in small-cell lung cancer 1048
 in thyroid carcinoma 1049
 in tumor angiogenesis 1043
 in vasodilation 1036
 inactivation of 1006
 lymphocyte functions of 1016
 neurotransmitter/neuromodulator role of 994
 pathological significance in human
 gastrointestinal tract 1024
 physiological significance in human
 gastrointestinal tract 1022
 primary structure of 963
 protochordate tachykinins as 965
 receptor antagonists of 994
 receptors for 963,994,1013
 receptors in human gastrointestinal tract 1021
 receptors in human malignancies 1043
 related peptides from invertebrates 966
 role in human gastrointestinal tract
 physiology/pathology 1021
 stimulation of vascular growth by 1035
 sub-mammalian vertebrate tachykinins as 965
 synthesis in respiratory system 1005
 synthesis of 993
 tissue-distribution of 963
- Tachykinin receptors antagonist 975
 multiple active type 985
- Tachykinin-related peptides 966
 biological actions of 970
 receptors for 966
- Targeted gene disruption 390
- TAT 1595
 encoded by two exons 1595
 gene expression of 1599
 interacts with PRMT6 1600
 is regulated by phosphorylation 1601
 mechanisms of *trans*-activation of 1597
 reverse transcription of 1602
 role of histone deacetylase/acetyl-
 transferase activity 1599
 structure/functions of 1595
- Taxanes 453
 plant cell culture technology for 458
 production of cultures of taxus species 453
- T-cell homeostasis 1573
 control of 1573
- Thermal injuries 121
 CC chemokines in 121
 CXC chemokines in 121
- Thiols 1238
 in function of glycoprotein Ib adhesion
 receptor 1238
- Thiopurine methyltransferase 1641
- Thrombosis 1243
- Thrombotic disorders 1245
 organic nitrates for 1245
- Thyroid hormone 203
 antidepressant effects of 203
 effects on noradrenergic system 204
 effects on serotonergic system 204
 mechanisms of 203
 mRNA effects of 208
 neuroendocrine studies of 207
 post-receptor effects of 209
- Transcription 683

- Transcription factors 589
 as target for asthma therapy 589
- Transforming growth factor- β (TGF- β) 547
 activation of 548
 binding proteins for 550
 expression in asthma 552
 expression of 548
 receptors for 550
 role in asthma 547
 role of isoforms in lung 551
 signaling pathway of 551
 therapeutic potential of 547
- Transport proteins 793
 classification of 793
- Trypanosoma cruzi* dihydroipoamide dehydrogenase 1155
 as target for phenothiazine cationic radicals .. 1155
 inactivation by peroxidase/H₂O₂ systems 1162
 protection by antioxidants against PTZ⁺
 radicals of 1167
- Tumor suppressor genes 416
- TYMS 1643
- Type 2 diabetes mellitus (T2DM) 211,1435
 ACE inhibitors in 221
 anti-diabetic drugs in 215
 anti-hypertensive drugs in 219
 anti-obesity drugs in 214
 HRT in 223
 hypolipidemic drugs in 218
 in high risk patients 211
 pharmacological interventions in 211,214
- Vascular thrombosis 1265
 collagen receptor in 1267
 inhibitory co-receptors in 1270
 platelet-collagen signaling in 1266
- Vaults 923
 cellular functions of 923
 cellular localization of 925
 functions of 925
- in multidrug resistance 923
 knock-out models of 929
 structure/components of 923
- Viral infectivity factor (Vif) 883,1583
 APOBEC3G interaction with 1585
 as therapeutic targets 883,1583,1590
 cellular interactions of 1583
 for antiretroviral therapy 883
 mechanisms of 1589
- Warfarin 1644
 dosing of 1644
- Yeast ABC transporters 471
 genetic analysis of 471
 phenotypic characterization of 471
- Yeast PDR network 476
 regulation of drug resistance genes within 476
- Zinc 607
 as targets in airway disease 607
 deficiency of 607
 deficiency of 608
 in airway inflammation 618
 in asthma 618
 in ciliated airway epithelial cells 613
 in homeostasis 607
 in normal airway epithelium 613
 intake/absorption of 608
 sub-cellular pools of 608
 transporters of 607
- Zinc metalloproteinases 614
- Zinc metalloproteins 614
 effect on airways 614
- Zinc transporters 607
 as targets in airway disease 607
 in lung/AE 614